Results 141 to 150 of about 30,845,260 (288)

Insights into GLP-1 Receptor Activation with a Nonpeptide Agonist [PDF]

Biochemistry, 2020
Thomas F. Martinez, Joan Vaughan, Alan Saghatelian   +2 more
openaire   +4 more sources

The Aesthetic Effects of GLP-1 Receptor Agonists: A Review

Supplemental material for our study "The Aesthetic Effects of GLP-1 Receptor Agonists: A Scoping ...
Hoang, Megan
core   +1 more source

Weight Loss Intentionality and Strategies in Urinary Incontinence

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Urinary incontinence (UI)−including stress (SUI), urge (UUI), and mixed (MUI) subtypes−is associated with obesity, and weight loss is commonly recommended for intervention. However, the comparative effects of intentionality and weight loss strategies on UI severity remain poorly defined.
Eric S. Chai, Jonathan T. Ryan, Vismitha Naik, Nicolas Tapia‐Stoll, Katherine A. Amin, Ricardo Palmerola, Adam Williams, Raveen Syan   +7 more
wiley   +1 more source

GLP-1 receptor agonists-a potential therapy for chronic kidney disease? [PDF]

Clin Sci (Lond)
Boeckhaus J, Sayer JA, Mabillard H.
europepmc   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

An Update on GLP‐1 Receptor Agonists

Journal of Diabetes
Zachary Bloomgarden
doaj   +1 more source

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. [PDF]

Nutr Clin Pract
Singhani V, Ehsan M, Valencia S, Nadeem A, Moazzam E, Butsch WS, Garg S.   +6 more
europepmc   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Unanticipated Effects of GLP-1 Receptor Agonists: A Net Positive. [PDF]

Obesity (Silver Spring)
Gilden AH, Heymsfield SB.
europepmc   +1 more source

How the Sea Salt Chocolate Cookie Became a Thing: The Role of Flavor Pairing in Obesity

Obesity, EarlyView.
Proposed framework illustrating how flavor pairing and multisensory flavor architecture may sustain hedonic eating through enhanced palatability, reward preservation, delayed sensory‐specific satiety, and post‐ingestive signaling, thereby promoting excess energy intake and obesity risk.
Mohammed Ayyad, Eugene Kim
wiley   +1 more source